|
|
| Line 1: |
Line 1: |
| <span style="color:navy">'''''SUMMARY TABLES'''''</span>
| |
|
| |
|
| | <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> |
|
| |
|
| {| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
| |
| |-
| |
| !colspan="7"|<span style="font-size:100%">'''CD13 expression: primitive cell types'''</font>
| |
| |-
| |
| ! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[ETP ALL|i]]''') !! MPAL '''[[MPAL|i]] || Hgns '''[[Hgns|i]]'''
| |
| |-
| |
| |style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|Limited Rare Possible Likely Frequent Expected
| |
| |style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
| |
| |style="width: 14.25%; background:#66e0ff; color:black"|Possible
| |
| |style="width: 14.25%; background: #E6FAFF; color:black"|Rare
| |
| |style="width: 14.25%; background: #00b8e6; color:black"|Likely
| |
| |style="width: 14.25%; background: #00b8e6; color:black"|Likely
| |
| |style="width: 14.25%; background: #66e0ff; color:black"|Possible
| |
| |-
| |
| |}
| |
|
| |
|
| <span style="font-size:90%">'''Notes:''' The main application is in AML (see notes for expression). Aberrant expression is seen in ALL - particularly in B-lineage, although it may be less likely in Burkitt lymphoma. CD13 is not generally expressed in T-ALL, but in the correct context CD13 expression can indicate MPAL or ETP-ALL. CD13 is reported to be expressed by some haematognes (click (i) for additional information) | | :<span style="color:navy">'''Summary'''</span> |
|
| |
|
| | :CD45 is expressed by almost all mature or maturing leucocytes: hence the name leukocyte common antigen. |
|
| |
|
| {| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
| | :Usefully, the level of expression of CD45 differs according to both the cell type it is expressed on, and the maturation stage of that cell. Generally the expression for any cell type is quite consistent. This means that, when combined with other markers (particularly light scatter parameters) CD45 can be used to make a provisional identification of the different leukocyte types, allow different populations to be analysed individually. |
| |-
| |
| !colspan="7"|'''CD13 expression: mature B cell neoplasms*'''
| |
| |-
| |
| ! CLL !! MCL !!FL!! MZL !! HCL !! LPL !! PCL
| |
| |-
| |
| |style= "width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |style="width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |style="width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |style= "width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |style="width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |style="width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |style="width: 14.2%; background: #E6FAFF; color:black"|rare
| |
| |-
| |
| |}
| |
|
| |
|
| <span style="font-size:90%">'''Notes:''' overall expression is uncommon in mature B-lymphoproliferative disorders, but may occur at plasma cell differentiation</span>
| | :Most frequently therefore the use of this antigen is for '''CD45 gating''' |
|
| |
|
|
| |
|
| | </div> |
|
| |
|
| {| class=wikitable style="text-align: center; font-size:80%; width: 71.4%; height 40px;"
| |
| |-
| |
| !colspan="7"|'''CD13 expression: mature T cell neoplasms*'''
| |
| |-
| |
| ! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
| |
| |-
| |
| |style= "width: 20%; background: #FFE4E1; color:black"|limited
| |
| |style="width: 20%; background: #FFE4E1; color:black"|limited
| |
| |style="width: 20%; background: #FFE4E1; color:black"|limited
| |
| |style= "width: 20%; background: #FFE4E1; color:black"|limited
| |
| |style="width: 20%; background: #FFE4E1; color:black"|limited
| |
| |-
| |
| |}
| |
|
| |
|
| <span style="font-size:90%">'''Notes:''' There is limited published evidence, but reports suggest expression of CD13 is uncommon in mature T cell malignancy</span> | | :<span style="color:navy">'''Background'''</span> |
|
| |
|
| ----
| | :xxxxxx |
|
| |
|
| '''KEY'''
| |
|
| |
|
| | :<span style="color:navy">'''Diagnostic Use'''</span> |
|
| |
|
| <span style="font-size:80%">'''''1. Colour key:''''' ''- the likelihood of any individual case expressing this marker, indicated by colour:''
| | *xxxxx |
| </span>
| |
|
| |
|
|
| |
|
| {| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
| | |
| |style= "width: 16.6%; background: #FFE4E1; |Few reported studies (though likely rare)
| | ----- |
| |}
| |
| {| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
| |
| |style= "width: 16.6%; background: #E6FAFF; |Expression may be seen, but is rare (<5%)
| |
| |}
| |
| {| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
| |
| |style="width: 16.6%; background: #66e0ff;"|Expression occurs in some cases (5-20%)
| |
| |}
| |
| {| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
| |
| |style="width: 16.6%; background: #00b8e6;"|Expression is likely to be encountered (20-40%)
| |
| |}
| |
| {| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
| |
| |style="width: 16.6%; background: #006699; color:white"|Epression is frequent (40-80%)
| |
| |}
| |
| {| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
| |
| |style="width: 16.6%; background: #004466; color:white"|Expect expression in most cases (80-100%)
| |
| |}
| |